ASK REDCHAT ANYTHING ABOUT GENPREX INC.
Genprex Inc. (NASDAQ: GNPX)
Listen to this Section
$0.50
+0.0329
(
+6.98% )
161.9K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| REQORSA (quaratusugene ozeplasmid) + TagrissoDetailsLung cancer, Non-small cell lung carcinoma, Cancer |
Phase 2a |
| REQORSA (quaratusugene ozeplasmid) + KeytrudaDetailsCancer, Non-small cell lung carcinoma, Lung cancer |
Phase 1/2 |
| REQORSA (quaratusugene ozeplasmid) + TecentriqDetailsLung cancer, Cancer, Small cell lung cancer |
Phase 1/2 |
Market Data
|
| Open |
$0.50 |
| Previous Close |
$0.47 |
| Volume |
161.9K |
| Market Cap |
$5.28M |
| Day Range |
$0.47 - $0.52 |
| 52 Week Range |
$0.42 - $55.00 |
| Shares Outstanding |
10.93M |
| Change % |
+6.98% |
| Net Change |
▲ 0.0329 |
| Insider Ownership |
-0.01% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2018 |
| Country | United States |
| Underwriter | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased:
-5,087.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2024-02-21 |
Sale |
-1126.00 |
Confer Ryan M. |
| 2024-02-21 |
Sale |
-2642.00 |
Varner John Rodney |
| 2024-02-21 |
Sale |
-1319.00 |
Berger Mark Stanley |